Please login to the form below

Not currently logged in
Email:
Password:

India's Supreme Court wants tighter clinical trial regulation

Justice Lodha says illegal studies of investigational medicines causing “havoc to human life”

India flag

The Indian government needs to do more to stop illegal, unregulated clinical trials, according to Supreme Court judge Justice RM Lodha.

Lodha made the comments during a hearing on a petition submitted by doctors and the non-profit organisation Swasthya Adhikar Manch, which claimed that citizens in the Madhya Pradesh region had been involved in drug trials without their permission.

As reported by the AFP, Lodha said: "Uncontrolled clinical trials are causing havoc to human life.

"There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far."

The matter is increasingly prominent, with India emerging as one of the main players in hosting clinical trials due to its relative low cost and recent improvements in access to healthcare.

However, this growth has not come with improved regulation or penalties for those who abuse the system, and Lodha, along with fellow judge Justice AR Dave, demanded the government do more.

As an interim measure they called for India's Health Minister Ghulam Nabi Azad to monitor all new applications from pharmaceutical companies wishing to launch trials in India.

Lodha, who has been a Supreme Court judge since 2008, has previously voiced his concerns about clinical trial practices in India, and in February 2012 he requested public-interest litigation in order to create a proper regulatory framework for checking illegal and unethical trials.

The regulatory system for medicines in India has also come under fire from the government itself in the past year, with the Ministry of Health calling for a revamp of the Central Drugs Standard Control Organization – the agency responsible agency responsible for regulating the pharmaceutical sector.

This followed an investigation from the Ministry of Health that implicated several companies, including Cipla, Sun Pharma, Novartis and Bayer, claiming that several studies had not met clinical trial requirements.

3rd January 2013

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics